LRIG2 promotes glioblastoma progression by modulating innate antitumor immunity through macrophage infiltration and polarization

Background Glioblastoma (GBM) is the most common malignant brain tumor with poor clinical outcomes. Immunotherapy has recently been an attractive and promising treatment of extracranial malignancies, however, most of clinical trials for GBM immunotherapy failed due to predominant accumulation of tumor-associated microglia/macrophages (TAMs). Results High level of LRIG2/soluble LRIG2 (sLRIG2) expression activates immune-related signaling pathways, which are associated with poor prognosis in GBM patients. LRIG2/sLRIGs promotes CD47 expression and facilitates TAM recruitment. Blockade of CD47-SIRP alpha interactions and inhibition of sLRIG2 secretion synergistically suppress GBM progression in an orthotropic murine GBM model. Conclusions GBM cells with high level LRIG2 escape the phagocytosis by TAM via the CD47-SIRP alpha axis, highlighting a necessity for an early stage of clinical trial targeting LRIG2 and CD47-SIRP alpha as a novel treatment for patients with GBM.

Automated summary

This study reveals that GBM cells with high level LRIG2 can escape phagocytosis by tumor-associated microglia/macrophages, highlighting the potential of early clinical trials targeting LRIG2 and CD47-SIRP alpha as a novel treatment for GBM.